PLoS ONE (Jan 2024)

Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.

  • Tarun Mehra,
  • Judith E Lupatsch,
  • Thibaud Koessler,
  • Konstantin Dedes,
  • Alexander Reinhard Siebenhüner,
  • Roger von Moos,
  • Andreas Wicki,
  • Matthias E Schwenkglenks

DOI
https://doi.org/10.1371/journal.pone.0315976
Journal volume & issue
Vol. 19, no. 12
p. e0315976

Abstract

Read online

[This corrects the article DOI: 10.1371/journal.pone.0301271.].